Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Link Between Agent Orange, Cancer Confirmed

May 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WASHINGTON--In an update of its 1994 report, the Institute of Medicine (IOM), of the National Academy of Sciences, has confirmed its original findings of an association between herbicides used in the Vietnam War and various health problems, namely, soft tissue sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and chloracne.

WASHINGTON--In an update of its 1994 report, the Institute ofMedicine (IOM), of the National Academy of Sciences, has confirmedits original findings of an association between herbicides usedin the Vietnam War and various health problems, namely, soft tissuesarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and chloracne.

The update also reported limited or suggestive epidemiologicalevidence for three newly discovered associations: a higher rateof spina bifida in children born to Vietnam vets, compared withnon-vets, and a higher incidence of transient peripheral neuropathyand por-phyria cutanea tarda in people exposed to herbicides ordioxin.

Between 1962 and 1970, US soldiers sprayed almost 20 million gallonsof Agent Orange and other defoliants over 3.6 million acres inVietnam. After studies linked Agent Orange to birth defects inlaboratory animals, the use of the chemical was suspended.

IOM committee chair David Tollerud, director of occupational andenvironmental medicine, University of Pittsburgh, said that "westill do not know the precise degree of risk from Agent Orangeexposure for individual Vietnam vet-erans, but the base of researchhas improved."

Articles in this issue

No Need to Delay Mammography After FNA, Study Shows
Pediatric Cancer Guidelines Are a National Effort
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutants
ATL's HDI Digital Ultrasound Is Approved for Breast Indication
Cell-Adhesion Molecules May Be Key to Controlling Metastases in Breast Cancer
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C
Natural History of HIV Supports the Use Of Early Interventions
Aids Vaccine Trial Fails to Show Clinical Benefit
Rep. Porter Honored For Work on Budget
Forum Airs Issue of Who Should Pay for Patient Care in Cancer Clinical Trials
Blenoxane Cleared for New Use In Malignant Pleural Effusion
Implementation of Critical Path Reduces Prostatectomy Costs
Berlex Foundation Seeks Workshop Applicants
Networking Venture Benefits Both
Health of Biotech Industry a Concern to Oncologists

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Related Content

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore
May 12th 2025
Article

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Related Content

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Rusfertide Combo Enhances Responses in Polycythemia Vera

Sabrina Serani
June 2nd 2025
Article

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore
May 12th 2025
Article

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.